Sophia Genetics, A.D.A.M Genetics partner for liquid biopsy testing

A.D.A.M. Innovations and SOPHiA GENETICS (SOPH) announced at ESMO a strategic agreement to bring liquid biopsy genomic testing to the Japanese population.The companies will also partner to commercialize a liquid biopsy companion diagnostic aimed at advancing personalized and precision cancer care in Japan. The partnership will initially focus on launching the liquid biopsy application, MSK-ACCESS powered with SOPHiA DDM. This liquid biopsy test is designed to detect actionable genomic alterations from a single blood draw, leveraging AI to analyze circulating tumor DNA in a minimally invasive manner. The test utilizes a matched tumor-normal approach which improves accuracy and avoids false positives. By launching the test locally and analyzing samples in-house, A.D.A.M. Innovations will expedite testing turnaround times, reduce costs to patients, and advance local cancer research. As part of the partnership, the companies also aim to develop a liquid biopsy companion diagnostic test in Japan